Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1751295
PUBLISHER: Grand View Research | PRODUCT CODE: 1751295
U.S. Equine Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Stem Cells, Platelet-Rich Plasma (PRP)), By Application, By End Use, By State, And Segment Forecasts, 2025 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Equine Regenerative Medicine Market Growth & Trends:
The U.S. equine regenerative medicine market size is expected to reach USD 80.44 million by 2030, registering a CAGR of 8.31% over the forecast period, according to a new report by Grand View Research, Inc. The primary factors driving the market growth are the increasing prevalence of musculoskeletal injuries in sport & performance horses, the growing integration of regenerative medicine into equine insurance & practice models, advancements in equine regenerative medicine, and the growing pet humanization & equine owner willingness to spend.
Musculoskeletal injuries such as tendonitis, ligament tears, joint damage, and osteoarthritis are increasingly common among sport and performance horses in the U.S. These injuries significantly reduce performance ability, lead to prolonged recovery, and may end careers prematurely. The rise in competitive equestrian events like show jumping, dressage, barrel racing, and endurance racing pushes horses to their physical limits, increasing the risk of soft tissue, joint injuries and other related complications. Traditional therapies (like NSAIDs, surgery) often result in incomplete healing and high rates of re-injury. Regenerative therapies, including platelet-rich plasma (PRP), stem cell therapy, and Pro-Stride (autologous protein solution), are gaining traction due to their ability to enhance tissue repair at the cellular level. These approaches promote faster recovery and can restore the horse to full athletic performance, reducing the risk of recurrence.
An example is the increased adoption of mesenchymal stem cell (MSC) therapy to treat suspensory ligament desmitis, a common injury in racehorses and jumpers. Studies show MSCs can reduce inflammation and improve tendon fiber alignment, leading to more complete healing. Clinics and referral hospitals now offer such treatments as standard, indicating strong market growth based on injury prevalence.
Furthermore, scientific innovations in veterinary regenerative medicine propel the market forward. Over the past decade, techniques for isolating, expanding, and delivering stem cells or biologic agents have become more efficient, cost-effective, and scalable. Understanding cell biology, tissue engineering, and biomaterials has improved treatment outcomes and broadened applications.
As per data published in February 2025 by Equine Network LLC, injectable gold therapy (GOLDIC) is emerging as a promising treatment for equine osteoarthritis (OA) and other musculoskeletal conditions. By incubating the horse's blood with hydrophilic gold particles, the therapy produces a serum rich in cytokines and growth factors that help reduce inflammation and promote regeneration. In a recent study, GOLDIC significantly improved symptoms of lameness, joint effusion, and swelling in horses, with many becoming asymptomatic after three to six months. As an innovative therapy that offers long-term relief compared to traditional treatments, it could gain traction among veterinarians and horse owners looking for more sustainable solutions. With proven efficacy in reducing inflammation and enhancing tissue regeneration, GOLDIC might encourage the adoption of more advanced orthobiologic treatments in the equine sector. This could increase demand for regenerative therapies, attracting more investment and potentially influencing the development of similar treatments for various musculoskeletal and soft tissue injuries in horses.
U.S. Equine Regenerative Medicine Market Report Highlights:
- Based on product, the stem cells segment held the largest market share of 61.75% in 2024. This can be attributed to its ability to promote proper tissue regeneration, improve healing quality, and reduce scar formation in joint, tendon, and ligament injuries. Strategic investments, such as Boehringer's acquisition of Global Stem Cell Technology, further accelerate innovation, positioning stem cells as a cornerstone of future equine healthcare.
- Based on application, the trauma/ wound care segment is expected to grow at the fastest CAGR of 8.65% over the forecast period. This can be attributed to the rising incidence of injuries and increasing awareness of equine health. Innovations in regenerative therapies-such as stem cells, PRP, autologous protein solutions, IRAP, and amniotic-derived products-significantly improve healing and reduce wound scarring. Products like Zarasyl's advanced wound care formulations showcase the potential of science-backed regenerative solutions. This rapid technological advancement positions trauma care as a key driver of future market growth
- By end use, the veterinary research institutes segment is expected to grow at the fastest CAGR of 8.75% during the forecast period. This can be owed to their pivotal role in innovation and clinical validation. Their research provides critical evidence supporting the safety and efficacy of regenerative treatments, encouraging wider clinical adoption. By driving breakthroughs in tissue repair and disease prevention, these institutes are shaping the future of equine healthcare.
- The state of Texas dominated the market in 2024 with a share of 16.61%. It is expected to grow rapidly, driven by rising demand for non-invasive treatments and innovations in stem cell and PRP therapies, and the presence of a large horse population. Strategic partnerships, acquisitions, and collaborations between biotech companies and veterinary institutions, like Ardent Equine's partnership with Pegasus Orthobiologics and Vetirus Pharmaceuticals' acquisition of Enso Discoveries, further enhance innovation and therapy development, positioning Florida as a leader in the sector.
Product Code: GVR-4-68040-586-8
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definition
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information/Data Analysis
- 1.6. Market Formulation & Visualization
- 1.7. Data Validation & Publishing
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.8.2. Volume Price Analysis
- 1.8.3. Global Market: CAGR Calculation
- 1.9. List of Secondary Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. North America Companion Animal Medicine Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing Prevalence of Musculoskeletal Injuries in Sport and Performance Horses
- 3.2.1.2. Increasing Integration of Regenerative Medicine into Equine Insurance and Practice Models
- 3.2.1.3. Advancements in Equine Regenerative Medicine
- 3.2.1.4. Growing Pet Humanization and Equine Owner Willingness to Spend
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Cost of Regenerative Therapies
- 3.2.2.2. Regulatory Ambiguity and Lack of Standardization
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.2.5. Industry Analysis - Porter's
- 3.2.5.1. Bargaining power of the suppliers
- 3.2.5.2. Bargaining power of the buyers
- 3.2.5.3. Threats of substitution
- 3.2.5.4. Threats from new entrants
- 3.2.5.5. Competitive rivalry
- 3.2.6. PESTEL Analysis
- 3.2.6.1. Political landscape
- 3.2.6.2. Economic and Social landscape
- 3.2.6.3. Technological landscape
- 3.2.1. Market Driver Analysis
- 3.3. Estimated Equine Population in U.S. Key States, 2024
- 3.4. Regulatory Framework
- 3.5. Equine Industry Demographics in the U.S.
- 3.5.1. Type of Breeds
- 3.5.2. Type of Activity (Sports & Others)
- 3.5.3. Equestrian Industry Facts & Figures
- 3.6. Pricing Analysis, by Product
- 3.7. Product Pipeline Analysis/Clinical Trials Analysis
- 3.8. Insurance Coverage Analysis
Chapter 4. U.S. Equine Regenerative Medicine Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. U.S. Equine Regenerative Medicine Market: By Product Movement Analysis, USD Million, 2024 & 2030
- 4.2.1. Stem Cells
- 4.2.1.1. Stem Cells Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 4.2.2. Platelet-Rich Plasma (PRP)
- 4.2.2.1. Platelet-Rich Plasma (PRP) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 4.2.3. Others
- 4.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 4.2.1. Stem Cells
Chapter 5. U.S. Equine Regenerative Medicine Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. U.S. Equine Regenerative Medicine Market: By Application Movement Analysis, USD Million, 2024 & 2030
- 5.2.1. Orthopedics
- 5.2.1.1. Orthopedics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.2.2. Trauma/ Wound Care
- 5.2.2.1. Trauma/ Wound Care Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.2.3. Others
- 5.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.2.1. Orthopedics
Chapter 6. U.S. Equine Regenerative Medicine Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. U.S. Equine Regenerative Medicine Market: By End Use Movement Analysis, USD Million, 2024 & 2030
- 6.2.1. Veterinary Hospitals/Clinics
- 6.2.1.1. Veterinary Hospitals/Clinics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.2.2. Veterinary Research Institutes
- 6.2.2.1. Veterinary Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.2.3. Others
- 6.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.2.1. Veterinary Hospitals/Clinics
Chapter 7. U.S. Equine Regenerative Medicine Market: State Estimates & Trend Analysis
- 7.1. State Market Share Analysis, 2024 & 2030
- 7.2. State Market Dashboard
- 7.3. State Market Snapshot
- 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
- 7.5. U.S.
- 7.5.1. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. Texas
- 7.5.2.1. Texas market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. California
- 7.5.3.1. California market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Florida
- 7.5.4.1. Florida market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. Ohio
- 7.5.5.1. Ohio market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Oklahoma
- 7.5.6.1. Oklahoma market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.7. Kentucky
- 7.5.7.1. Kentucky market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.8. Missouri
- 7.5.8.1. Missouri market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.9. Pennsylvania
- 7.5.9.1. Pennsylvania market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.10. Colorado
- 7.5.10.1. Colorado market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.11. Other States
- 7.5.11.1. Other States market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Participant Categorization
- 8.2. Company Market Position Analysis/ Heat Map Analysis
- 8.3. Company Profile
- 8.3.1. Boehringer Ingelheim International GmbH
- 8.3.1.1. Company overview
- 8.3.1.2. Financial performance
- 8.3.1.3. Product benchmarking
- 8.3.1.4. Strategic initiatives
- 8.3.2. Zoetis
- 8.3.2.1. Company overview
- 8.3.2.2. Financial performance
- 8.3.2.3. Product benchmarking
- 8.3.2.4. Strategic initiatives
- 8.3.3. Dechra Pharmaceuticals Plc
- 8.3.3.1. Company overview
- 8.3.3.2. Financial performance
- 8.3.3.3. Product benchmarking
- 8.3.3.4. Strategic initiatives
- 8.3.4. Equine Amnio Solutions
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. VetStem, Inc.
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Hilltop Bio
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Equi-Stem LLC
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Ardent Equine
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Pronoia Biotech
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Medrego
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. AniCell BioTech
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. PetVivo Holdings, Inc. (Spyrng)
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Product benchmarking
- 8.3.12.4. Strategic initiatives
- 8.3.13. Arthrex Inc.
- 8.3.13.1. Company overview
- 8.3.13.2. Financial performance
- 8.3.13.3. Product benchmarking
- 8.3.13.4. Strategic initiatives
- 8.3.14. Contura Vet
- 8.3.14.1. Company overview
- 8.3.14.2. Financial performance
- 8.3.14.3. Product benchmarking
- 8.3.14.4. Strategic initiatives
- 8.3.15. Nucleus ProVets LLC
- 8.3.15.1. Company overview
- 8.3.15.2. Financial performance
- 8.3.15.3. Product benchmarking
- 8.3.15.4. Strategic initiatives
- 8.3.16. Enso Discoveries (Vetirus Pharmaceuticals)
- 8.3.16.1. Company overview
- 8.3.16.2. Financial performance
- 8.3.16.3. Product benchmarking
- 8.3.16.4. Strategic initiatives
- 8.3.17. Gallant Therapeutics
- 8.3.17.1. Company overview
- 8.3.17.2. Financial performance
- 8.3.17.3. Product benchmarking
- 8.3.17.4. Strategic initiatives
- 8.3.18. Astaria Global
- 8.3.18.1. Company overview
- 8.3.18.2. Financial performance
- 8.3.18.3. Product benchmarking
- 8.3.18.4. Strategic initiatives
- 8.3.19. Interpath Global (4CYTE)
- 8.3.19.1. Company overview
- 8.3.19.2. Financial performance
- 8.3.19.3. Product benchmarking
- 8.3.19.4. Strategic initiatives
- 8.3.20. American Regent, Inc.
- 8.3.20.1. Company overview
- 8.3.20.2. Financial performance
- 8.3.20.3. Product benchmarking
- 8.3.20.4. Strategic initiatives
- 8.3.1. Boehringer Ingelheim International GmbH
- 8.4. Strategy Mapping
- 8.4.1. Mergers & Acquisitions
- 8.4.2. Partnerships & Collaborations
- 8.4.3. Expansion
- 8.4.4. Product launch
- 8.4.5. Others
- 8.5. List of other Key players
Product Code: GVR-4-68040-586-8
List of Tables
- Table 1. List of Secondary Sources
- Table 2. List of Abbreviations
- Table 3. Estimated Equine Population in U.S. key states, 2024.
- Table 4. Pricing analysis by key products
- Table 5. U.S. Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 6. U.S. Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 7. U.S. Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 8. U.S. Equine Regenerative Medicine Market, by State, 2018 - 2030 (USD Million)
- Table 9. Texas Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 10. Texas Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 11. Texas Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 12. California Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 13. California Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 14. California Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 15. Florida Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 16. Florida Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 17. Florida Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 18. Ohio Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 19. Ohio Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 20. Ohio Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 21. Oklahoma Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 22. Oklahoma Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 23. Oklahoma Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 24. Kentucky Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 25. Kentucky Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 26. Kentucky Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 27. Missouri Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 28. Missouri Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 29. Missouri Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 30. Pennsylvania Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 31. Pennsylvania Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 32. Pennsylvania Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 33. Colorado Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 34. Colorado Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 35. Colorado Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 36. Other States Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
- Table 37. Other States Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
- Table 38. Other States Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
- Table 39. Company Overview
- Table 40. Product Benchmarking
- Table 41. Financial Performance
- Table 42. Strategic Initiatives
List of Figures
- Fig. 1 Market research process
- Fig. 2 Information Procurement
- Fig. 3 Primary Research Pattern
- Fig. 4 Market Research Approaches
- Fig. 5 Value Chain-Based Sizing & Forecasting
- Fig. 6 Market Formulation & Validation
- Fig. 7 Equine Regenerative Medicine Market, Market Segmentation
- Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
- Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
- Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
- Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
- Fig. 12 Porter's Five Forces Analysis
- Fig. 13 State Marketplace: Key Takeaways
- Fig. 14 U.S. Equine Regenerative Medicine Market, for Product, 2018 - 2030 (USD Million)
- Fig. 15 U.S. Equine Regenerative Medicine Market, for Stem Cells, 2018 - 2030 (USD Million)
- Fig. 16 U.S. Equine Regenerative Medicine Market, for Platelet-Rich Plasma (PRP), 2018 - 2030 (USD Million)
- Fig. 17 U.S. Equine Regenerative Medicine Market, for Others , 2018 - 2030 (USD Million)
- Fig. 18 U.S. Equine Regenerative Medicine Market, for Application, 2018 - 2030 (USD Million)
- Fig. 19 U.S. Equine Regenerative Medicine Market, for Orthopedics, 2018 - 2030 (USD Million)
- Fig. 20 U.S. Equine Regenerative Medicine Market, for Trauma/Wound Care, 2018 - 2030 (USD Million)
- Fig. 21 U.S. Equine Regenerative Medicine Market, for Others, 2018 - 2030 (USD Million)
- Fig. 22 U.S. Equine Regenerative Medicine Market, for End Use, 2018 - 2030 (USD Million)
- Fig. 23 U.S. Equine Regenerative Medicine Market, for Veterinary Hospitals/Clinics, 2018 - 2030 (USD Million)
- Fig. 24 U.S. Equine Regenerative Medicine Market, for Veterinary Research Institutes, 2018 - 2030 (USD Million)
- Fig. 25 U.S. Equine Regenerative Medicine Market, for Others, 2018 - 2030 (USD Million)
- Fig. 26 State Outlook, 2024 & 2030
- Fig. 27 Texas Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 28 California Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 29 Florida Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 30 Ohio Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 31 Oklahoma Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 32 Kentucky Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 33 Missouri Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 34 Pennsylvania Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 35 Colorado Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 36 Other States Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
- Fig. 37 Market participant categorization
- Fig. 38 Heat map analysis
- Fig. 39 Strategic Framework
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.